Financhill
Sell
38

APLT Quote, Financials, Valuation and Earnings

Last price:
$0.52
Seasonality move :
19.13%
Day range:
$0.50 - $0.55
52-week range:
$0.43 - $10.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.79x
Volume:
1.5M
Avg. volume:
2.5M
1-year change:
-90.92%
Market cap:
$63.6M
Revenue:
$10M
EPS (TTM):
-$1.61

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
APLT
Applied Therapeutics
$100K -$0.18 -76.55% -43.43% $5.50
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
RVPH
Reviva Pharmaceuticals Holdings
-- -$0.22 -- -30.3% $12.14
SAVA
Cassava Sciences
-- -$0.68 -- -36% --
VSTM
Verastem
$150K -$0.74 -- -28.48% $12.57
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
APLT
Applied Therapeutics
$0.55 $5.50 $63.6M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
PTN
Palatin Technologies
$0.81 $7.00 $21.1M -- $0.00 0% --
RVPH
Reviva Pharmaceuticals Holdings
$1.10 $12.14 $36.8M -- $0.00 0% --
SAVA
Cassava Sciences
$2.78 -- $134.3M -- $0.00 0% 3.15x
VSTM
Verastem
$7.23 $12.57 $321.8M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
APLT
Applied Therapeutics
-- 0.844 -- 1.00x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
PTN
Palatin Technologies
-- -1.737 -- 0.99x
RVPH
Reviva Pharmaceuticals Holdings
-- -0.897 -- --
SAVA
Cassava Sciences
-- -3.511 -- --
VSTM
Verastem
50.52% 0.070 40.34% 3.10x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
APLT
Applied Therapeutics
-- -$29.7M -790.52% -797.82% -24379.51% -$23.3M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M
RVPH
Reviva Pharmaceuticals Holdings
-- -$8.5M -- -- -- -$4.2M
SAVA
Cassava Sciences
-- -$30.3M -- -- -- -$61.3M
VSTM
Verastem
-- -$37M -78.01% -120.71% -71.18% -$23.8M

Applied Therapeutics vs. Competitors

  • Which has Higher Returns APLT or NBY?

    NovaBay Pharmaceuticals has a net margin of -56222.13% compared to Applied Therapeutics's net margin of -49.65%. Applied Therapeutics's return on equity of -797.82% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    APLT
    Applied Therapeutics
    -- -$0.48 $5.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About APLT or NBY?

    Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Applied Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Applied Therapeutics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLT
    Applied Therapeutics
    2 3 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is APLT or NBY More Risky?

    Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock APLT or NBY?

    Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLT or NBY?

    Applied Therapeutics quarterly revenues are $122K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Applied Therapeutics's net income of -$68.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLT
    Applied Therapeutics
    -- -- $122K -$68.6M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns APLT or PTN?

    Palatin Technologies has a net margin of -56222.13% compared to Applied Therapeutics's net margin of -2357.27%. Applied Therapeutics's return on equity of -797.82% beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    APLT
    Applied Therapeutics
    -- -$0.48 $5.9M
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About APLT or PTN?

    Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 764.09%. Given that Applied Therapeutics has higher upside potential than Palatin Technologies, analysts believe Applied Therapeutics is more attractive than Palatin Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLT
    Applied Therapeutics
    2 3 0
    PTN
    Palatin Technologies
    0 0 0
  • Is APLT or PTN More Risky?

    Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock APLT or PTN?

    Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLT or PTN?

    Applied Therapeutics quarterly revenues are $122K, which are smaller than Palatin Technologies quarterly revenues of $350K. Applied Therapeutics's net income of -$68.6M is lower than Palatin Technologies's net income of -$2.4M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLT
    Applied Therapeutics
    -- -- $122K -$68.6M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M
  • Which has Higher Returns APLT or RVPH?

    Reviva Pharmaceuticals Holdings has a net margin of -56222.13% compared to Applied Therapeutics's net margin of --. Applied Therapeutics's return on equity of -797.82% beat Reviva Pharmaceuticals Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    APLT
    Applied Therapeutics
    -- -$0.48 $5.9M
    RVPH
    Reviva Pharmaceuticals Holdings
    -- -$0.25 --
  • What do Analysts Say About APLT or RVPH?

    Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand Reviva Pharmaceuticals Holdings has an analysts' consensus of $12.14 which suggests that it could grow by 1003.9%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Applied Therapeutics, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Applied Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLT
    Applied Therapeutics
    2 3 0
    RVPH
    Reviva Pharmaceuticals Holdings
    3 0 0
  • Is APLT or RVPH More Risky?

    Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison Reviva Pharmaceuticals Holdings has a beta of -0.095, suggesting its less volatile than the S&P 500 by 109.539%.

  • Which is a Better Dividend Stock APLT or RVPH?

    Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reviva Pharmaceuticals Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Reviva Pharmaceuticals Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLT or RVPH?

    Applied Therapeutics quarterly revenues are $122K, which are larger than Reviva Pharmaceuticals Holdings quarterly revenues of --. Applied Therapeutics's net income of -$68.6M is lower than Reviva Pharmaceuticals Holdings's net income of -$8.4M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Reviva Pharmaceuticals Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus -- for Reviva Pharmaceuticals Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLT
    Applied Therapeutics
    -- -- $122K -$68.6M
    RVPH
    Reviva Pharmaceuticals Holdings
    -- -- -- -$8.4M
  • Which has Higher Returns APLT or SAVA?

    Cassava Sciences has a net margin of -56222.13% compared to Applied Therapeutics's net margin of --. Applied Therapeutics's return on equity of -797.82% beat Cassava Sciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    APLT
    Applied Therapeutics
    -- -$0.48 $5.9M
    SAVA
    Cassava Sciences
    -- -$0.57 --
  • What do Analysts Say About APLT or SAVA?

    Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4072.66%. Given that Cassava Sciences has higher upside potential than Applied Therapeutics, analysts believe Cassava Sciences is more attractive than Applied Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLT
    Applied Therapeutics
    2 3 0
    SAVA
    Cassava Sciences
    0 2 0
  • Is APLT or SAVA More Risky?

    Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -1.240, suggesting its less volatile than the S&P 500 by 224.042%.

  • Which is a Better Dividend Stock APLT or SAVA?

    Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLT or SAVA?

    Applied Therapeutics quarterly revenues are $122K, which are larger than Cassava Sciences quarterly revenues of --. Applied Therapeutics's net income of -$68.6M is lower than Cassava Sciences's net income of -$27.6M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus 3.15x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLT
    Applied Therapeutics
    -- -- $122K -$68.6M
    SAVA
    Cassava Sciences
    3.15x -- -- -$27.6M
  • Which has Higher Returns APLT or VSTM?

    Verastem has a net margin of -56222.13% compared to Applied Therapeutics's net margin of -82.56%. Applied Therapeutics's return on equity of -797.82% beat Verastem's return on equity of -120.71%.

    Company Gross Margin Earnings Per Share Invested Capital
    APLT
    Applied Therapeutics
    -- -$0.48 $5.9M
    VSTM
    Verastem
    -- -$0.60 $80.9M
  • What do Analysts Say About APLT or VSTM?

    Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand Verastem has an analysts' consensus of $12.57 which suggests that it could grow by 73.88%. Given that Applied Therapeutics has higher upside potential than Verastem, analysts believe Applied Therapeutics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLT
    Applied Therapeutics
    2 3 0
    VSTM
    Verastem
    6 0 0
  • Is APLT or VSTM More Risky?

    Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison Verastem has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.46%.

  • Which is a Better Dividend Stock APLT or VSTM?

    Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLT or VSTM?

    Applied Therapeutics quarterly revenues are $122K, which are smaller than Verastem quarterly revenues of $10M. Applied Therapeutics's net income of -$68.6M is lower than Verastem's net income of -$24M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLT
    Applied Therapeutics
    -- -- $122K -$68.6M
    VSTM
    Verastem
    -- -- $10M -$24M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock